Also known as: PNB-0408
Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. It is considered one of the most potent cognitive enhancers ever tested in animal models — reportedly 7 orders of magnitude more potent than BDNF at improving cognitive performance in rodent Alzheimer's models.
Overview
At A Glance
Dihexa is a small-molecule analog derived from angiotensin IV (AngIV). It retains the Tyr-Ile core of Nle1-AngIV, with an N-terminal hexanoic acid cap and a C-terminal 6-aminohexanoic amide that give it metabolic stability and blood-brain-barrier penetration. In rodent studies it…
Overview
Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. It is considered one of the most potent cognitive enhancers ever tested in animal models — reportedly 7 orders of magnitude more potent than BDNF at improving cognitive performance in rodent Alzheimer's models. Exclusively used by the research and biohacking community with no human clinical trial data available.
Potential Research Fields
What to Expect
- •No human efficacy data exists, so any effect in people is anecdotal and unverified
- •Anecdotal users describe subtle improvements in mental clarity or verbal fluency over days to weeks; these reports are unblinded and unreliable
- •Effects, if any, are attributed to synaptic remodeling rather than acute stimulation
- •Because safety is unstudied, treat any use as a personal experiment with unknown long-term risk
Individual responses vary. Timeline based on commonly reported research observations.
Chemical Information
IUPAC Name
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
CAS Number
1191170-93-0
Molecular Formula
C27H44N4O5
Molecular Mass
504.7 g/mol
Amino Acid Sequence
Dosing & Protocols
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
- Dose, route, how often and how long
- A titration schedule
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Research
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Interactions
Interaction Matrix
Contraindications
Active cancer or a personal history of cancer (HGF/c-Met is an oncogenic pathway); do not use without oncologist oversight. Pregnancy or breastfeeding. History of seizures. Active neurodegenerative disease (unstudied interaction). Concurrent use of other potent nootropics without careful titration. When in doubt, do not use; there is no human safety data.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$79.99
up to $99.99
$0.2833
1
3
nasal, liquid
Tracking since Sep 5, 2026 · 3 data points
Vendors Selling Dihexa
How we score these vendors
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
Fasoracetam (NS-105)
NootropicsPhase 2Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia.
Side-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for Dihexa
Related Articles
All PostsResearch Score
1 PubMed result
Quality Indicators
Data Completeness
100%Research Volume
Limited research available
Quick Facts
Half-Life
Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence.
Molecular Weight
504.7 g/mol
Administration
Oral, Intranasal, Subcutaneous
CAS Number
1191170-93-0
Trial Phase
Preclinical
Safety Profile
Moderate RiskCommon Side Effects
- • No controlled human safety data exists
- • Anecdotal: headache, fatigue, irritability or anxiety, insomnia, vivid dreams
Stop Use If
- CRITICAL: active cancer or cancer history; HGF/c-Met is a known oncogenic pathway; do not use without medical supervision
- New or worsening neurological symptoms such as severe headache, mood change, or seizure
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
Is Dihexa approved or proven to work in humans?
No. Dihexa has never been through a human clinical trial. All evidence is from rodent studies, and it is sold only for research use. Any human use is experimental and unproven.
How does Dihexa work?
In animal studies it promotes the growth of new synapses in the hippocampus. Its proposed mechanism is potentiation of the HGF/c-Met system with downstream PI3K/Akt signaling, but the main paper establishing the HGF/c-Met binding target was retracted in 2025, so the exact target is unconfirmed.
What is the biggest safety concern with Dihexa?
The HGF/c-Met pathway it targets is also involved in tumor growth and metastasis, which creates a theoretical cancer risk with long-term use. Anyone with active or prior cancer should avoid it, and no one should assume it is safe, because there is no human safety data.
What doses do people use?
There is no established human dose. Anecdotal oral use ranges from about 5 to 40 mg once daily in short cycles. These figures are community-derived, not evidence-based.
Is Dihexa the same as Athira's Alzheimer's drug?
No. Athira Pharma (formerly M3 Biotechnology) grew out of the same Washington State University HGF/c-Met research, but its clinical candidate fosgonimeton (ATH-1017) is a different molecule. Dihexa itself remained preclinical.
Research Tools
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
Fasoracetam (NS-105)
NootropicsPhase 2Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia.
Side-by-Side Comparisons
All ComparisonsCompare Dihexa head-to-head: mechanism, half-life, dosing, safety, and vendor prices.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.